$29.86
-1.94-6.1%
Last update: Nov 12, 4:00 PM
Amylyx Pharmaceuticals Inc
AMLXNASDAQ
Amylyx Pharmaceuticals rose 157.9% from $12.33 to $31.80, ahead of the S&P 500's +10.8%. Its worst day was Mar 3 (−7.8%), and its low came Jan 6 at $11.38.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Amylyx Pharmaceuticals closed at its lowest level of the year, 7.7% below where the year started.
−0.1% · S&P 500 +0.6%
Amylyx Pharmaceuticals shares rose 15.7%, while the S&P 500 fell 2.0%.
+15.7% · S&P 500 −2.0%
Story events cover the past 12 months · Times ET
EPS of $-0.30 beat the $-0.33 estimate on $0.00 revenue.
−7.8%, the year's worst day · S&P 500 −0.9%
EPS of $-0.37 missed the $-0.34 estimate on $0.00 revenue.
−5.4% · S&P 500 −0.3%
EPS of $-0.39 missed the $-0.35 estimate on $0.00 revenue.
+10.7% · S&P 500 −0.2%
Amylyx Pharmaceuticals closed at its highest level of the year, 221.7% above where the year started.
+2.7% · S&P 500 −0.8%
EPS of $-0.38 missed the $-0.37 estimate on $0.00 revenue (est. $41,600.00).
−6.1% · S&P 500 −4.4%
Where it ended: a close of $31.80 on Nov 11, 2026. Up next: Q4 2026 earnings on Mar 2, 2027 (EPS est. $-0.37, revenue est. $8,400.00).
Nothing in the past 12 months.
All AMLX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AMLX and SPY from Benzinga historical bars. Not investment advice.
